30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
In re Oracle Corp. Derivative Litig, Consol. C.A. No. 2017-0337-SG (Del. Ch. June 22, 2020) - At th...
Read More >
Software Company Fired Employee for Perceived Disability, Federal Agency Charged - RALEIGH, N.C. -...
Read More >
In an effort to update UK discrimination law, the Women and Equalities Committee of the UK Parliamen...
Read More >
Synopsis: As the 2020 presidential election approaches, both Congress and the presidential candidate...
Read More >
POWER INTEGRATIONS, INC v. SEMICONDUCTOR COMPONENTS - Before Prost, Reyna, and Stoll. Appeal from ...
Read More >
Businesses may receive a bit of breathing room as a result of two amendments to the California Consu...
Read More >